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Prior to invading the nervous system, prions fre-
quently colonize lymphoid organs and sites of
inflammatory lymphoneogenesis, where they colocal-
ize with Mfge8+ follicular dendritic cells (FDCs). Here,
we report that soft-tissue granulomas, a frequent
feature of chronic inflammation, expressed the cellu-
lar prion protein (PrPC, encoded byPrnp) and the lym-
photoxin receptor (LTbR), even though they lacked
FDCs anddid not display lymphoneogenesis. After in-
traperitoneal prion inoculation, granulomas of Prnp+/+
mice, but not Prnp/ granulomas or unaffected
Prnp+/+ skin, accumulated prion infectivity and
disease-associated prion protein. Bone-marrow
transfers between Prnp+/+ and Prnp/ mice and
administration of lymphotoxin signaling antagonists
indicated that prion replication required radioresist-
ant PrPC-expressing cells and LTbR signaling. Granu-
lomatous PrPC was mainly expressed by stromal
LTbR+ mesenchymal cells that were absent from
unaffected subcutis. Hence, granulomas can act as
clinically silent reservoirs of prion infectivity. Further-
more, lymphotoxin-dependent prion replication can
occur in inflammatory stromal cells that are distinct
from FDCs.
INTRODUCTION
Transmissible spongiform encephalopathies (TSEs) are infec-
tious neurodegenerative disorders of humans and animals
caused by unconventional pathogens termed prions (Aguzzi
and Polymenidou, 2004). Throughout this paper, we refer to
the ‘‘prion’’ as the infectious agent causing TSEs, without imply-
ing that it consists of any specific biophysical entity. Accordingly,
prion infectivity is measured by microbiological bioassays and
expressed as titer of LD50 and ID50 units in vivo and in vitro,
respectively (Aguzzi and Weissmann, 1997).
PrPSc, an aggregated, partially proteinase-K (PK) resistant
isoform of the cellular host prion protein PrPC, accumulates in998 Immunity 29, 998–1008, December 19, 2008 ª2008 Elsevier Ininfected organisms and may represent the disease-associated
prion (Legname et al., 2004). PrPC is required as a substrate
for prion replication and disease development, and Prnp/
mice lacking PrPC are resistant to prion infections (Bu¨eler et al.,
1993) and to PrPSc neurotoxicity (Brandner et al., 1996).
Although TSEs selectively damage the CNS, extraneural PrPC
is needed for prion transport from peripheral sites to the CNS
(Bla¨ttler et al., 1997), and in most TSEs, PrPSc is detectable in
lymphoid organs long before clinical signs (Fraser and Dickin-
son, 1970; Glatzel et al., 2003). In addition to PrPC (Bu¨eler
et al., 1993), splenic prion replication requires follicular dendritic
cells (FDCs) whose maintenance crucially depends on B cells
expressing tumor necrosis factor (TNF) and lymphotoxin
a (LTa) and LTb (Prinz et al., 2003). Accordingly, genetic ablation
of LT or TNF receptors antagonizes peripheral prion replication
(Mabbott et al., 2002; Prinz et al., 2002), and B cell-deficient
mice lacking FDCs are resistant to peripheral prion administra-
tion (Klein et al., 1997; Klein et al., 1998; Montrasio et al.,
2001). Suppression of LTb receptor (LTbR) signaling by
administration of soluble dimeric LTbR (LTbR-Fc) dedifferenti-
ates mature FDCs and impairs peripheral prion pathogenesis
(Mabbott et al., 2000; Mabbott et al., 2003; Montrasio et al.,
2000).
Certain chronic inflammatory and neoplastic conditions
(Hamir et al., 2006; Heikenwalder et al., 2005; Ligios et al.,
2005) enable local PrPSc deposition and prion replication and
also display extravasation of B cells and ectopic maturation of
FDCs, supporting the idea that FDCs are the primary site of
extraneural prion replication. However, not all extraneural prion
deposition depends on FDCs. Myocytes and fibroblasts repli-
cate prions in vitro (Dlakic et al., 2007; Mahal et al., 2007; Vorberg
et al., 2004) and possibly in vivo (Andreoletti et al., 2004), sug-
gesting that replication is not restricted to immune and neuroec-
todermal cells. PrPSc was found in many nonlymphoid sites of
patients with Creutzfeldt-Jakob disease and of animals with
TSEs (Glatzel et al., 2003; Mathiason et al., 2006; Vascellari
et al., 2007). Finally, prion replication can occur in lymph nodes
of TNF receptor 1 (TNFR1)-deficient mice that lack FDCs (Old-
stone et al., 2002; Prinz et al., 2002). The cells replicating prions
in this context have not been characterized.
Thus, there are considerable uncertainties on the nature of the
cells replicating prions in extraneural compartments. Here, wec.
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Lymphotoxin and Prion Replication in Granulomasinvestigated conditions in which immune cells would focally
accumulate at sites of inflammation, yet no FDCs would be
induced. Granulomas fulfill these criteria because they consist
mainly of specialized macrophages surrounded by fibroblasts
and lymphocytes. Granulomas are highly prevalent in humans
and farm animals and can develop at any site of the body in
diseases of disparate etiology (Kumar et al., 2004). PrPC was
enriched in mesenchymal CD45LTbR+ cells within granulomas,
with concentrations similar to lymphoid tissue. Prnp+/+ granulo-
mas were rapidly colonized by prions. Despite the absence of
FDCs, suppression of lymphotoxin signaling reduced the prion
load of granulomas. Therefore, a select population of inflamma-
tory stromal cells of granulomas can replicate prions upon LTbR
signaling.
RESULTS
Induction and Characterization of Granulomas
Granulomas were induced subcutaneously (s.c.) at two symmet-
ric abdominal sites in Prnp+/+, Prnp/ mice and in tga20 mice
(all C57BL/6x129Sv hybrids) overexpressing PrPC under the
control of the Prnp promoter (Fischer et al., 1996) by injection
of complete Freund’s adjuvans (CFA) or Zymosan resuspended
in paraffin oil (Z/PFO). Twenty-five days before prion inoculation
(25 d), granulomas were boosted by reinjection of the inducer
Figure 1. Generation, Prion Inoculation, and Histo-
logical Analysis of Granulomas
(A) Time line of granuloma generation, prion inoculation,
and organ collection. ‘‘Dpi’’ refers to days after inocula-
tion.
(B) The left panel shows hematoxylin and eosin (H&E)
staining of a representative granuloma nodule. The dotted
area and inset show detail of an epitheloid macrophage
(indicated by an arrowhead). The scale bar represents
150 mm. The center panel shows the scheme of the gran-
uloma depicted on the left, with delineation of the various
components. The right panel shows detail of granuloma
with multinucleated giant cells (indicated by arrowheads),
collagen bundles (reddish streaks), and fibroblasts
(elongated cells). The scale bar represents 100 mm.
(C) Immunohistological characterization of granuloma
nodules at 55 dpi. CD68, CD11c, and CD11b stains
were performed to detect macrophages and epitheloid
cells. CD3 and B220 stains were used for detecting
T and B lymphocytes, respectively. Asterisks indicate lipid
vacuoles. The scale bar represents 250 mm.
mix at the primary injection sites (Figure 1A).
This reliably induced granulomas in all mice
and ensured granuloma maintenance for at
least 145 days. The diameter of granuloma nod-
ules ranged between 1 and 10 mm at 145 days
after granuloma induction (‘‘dpgi’’). At 50 dpgi
mice were inoculated intraperitoneally (i.p.)
with prions (strain RML5; 5 logLD50 in 100 ml).
Granulomas were dissected at 55 or 95 days af-
ter prion inoculation (‘‘dpi’’) and displayed at
each time point the characteristic cellular com-
position and morphology of granulomas (Figure 1 and Figures
S1, S2, and S3 available online).
Z/PFO induced accumulations of foamy macrophages with
degenerating neutrophils (Figure S2A). In contrast, CFA-induced
granulomas closely resembled their human counterparts with
central pockets of lipid vacuoles, epitheloid macrophages
(Figure 1B, left, arrowhead), multinucleated giant cells
(Figure 1B, right arrowheads), neovascularization, and fibrous
capsules (Figure 1B). Therefore, further analyses focused on
CFA-induced granulomas. Granulomas contained predominantly
CD68+CD11c+CD11b+MHC-II+ cells, most of which were nega-
tive for the pan-dendritic cell marker NLDC (Figure S1D) and
therefore classified as macrophages (Ordway et al., 2005). Gran-
ulomas also contained few Ly6G+ granulocytes (Figure S1B), as
well as scattered CD3+ and B220+CD19+ cells (Figure 1D and
Figure S1A).
Larger B220+ cell aggregates were visible at the outer rim of
the inflammatory foci (Figure S1B). These aggregates were
negative for FDC-M1, CD35, C1qa and FDC-M2 (Figure S1B),
suggesting the absence of FDCs. This was further investigated
by real-time PCR analysis for the FDC-M1 antigen, Mfge8
(Kranich et al., 2008). Mfge8 mRNA content of granulomas
was indistinguishable from that of Mfge8/ spleens, or Ltbr/
spleens (Figure S1C), confirming that granulomas were devoid
of FDCs.Immunity 29, 998–1008, December 19, 2008 ª2008 Elsevier Inc. 999
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Lymphotoxin and Prion Replication in GranulomasMolecular Characterization of Granulomas before
and after Prion Inoculation
At 0, 55, and 95 dpi, Prnp mRNA expression in Prnp+/+ granulo-
mas was similar to or lower (50%–15%) than that of untreated or
prion-inoculated Prnp+/+ spleens (Figure 2A). In contrast, Prnp
transcripts were not detectable in nongranulomatous Prnp+/+
subcutaneous tissue or in Prnp/ granulomas and spleens
(data not shown).
Tnf and Ccl2 transcripts in Prnp+/+ and Prnp/ granulomas at
both 55 and 95 dpi were 16- and 64-fold higher, respectively,
than in Prnp+/+ spleens andR128 fold higher than in nongranu-
lomatous Prnp+/+ subcutaneous tissue (Figure 2A). Ltbr mRNA
expression in granulomas was%50%–10% less than in nonino-
culated Prnp+/+ spleens (0, 55, and 95 dpi), whereas unaffected
subcutaneous tissue contained very little Ltbr mRNA (Figure 2A).
Il6 and Tgfb1 were transcribed similarly in granulomas and
spleens, yet were undetectable in unaffected subcutaneous
tissue. The homeostatic chemokines Ccl21, Cxcl13, Ccl19,
and Cx3cl1 were weakly transcribed or undetectable in Prnp+/+
and Prnp/ granulomas and subcutaneous tissue (Figure S2).
Hence, CFA-induced granulomas expressed relatively abundant
Prnp transcripts and recapitulated the expression of proteins in-
volved in the formation of human granulomas (Russell, 2007).
Quantification of PrP Protein in Granulomas
PrPC concentrations in granuloma homogenates (CFA or Z/PFO
induced) of Prnp+/+ and tga20 mice were similar to those of the
Figure 2. Molecular Characterization of
Granulomas
(A) Real-time PCR analysis of Prnp, Tnf, Ccl2, Ltbr,
Tgfb1, and Il6 mRNA expression in spleens
(circles) and granulomas (triangles) of prion-inocu-
lated Prnp+/+ (red) and Prnp/ (black) mice (55
and 95 dpi). Each data point represents the aver-
age of three measurements from one individual
organ sample. The average of naive Prnp+/+
spleens (n = 3) was set as the baseline. Prnp/,
Ltbr/, and Tnf/ mice were used as negative
controls (n = 3, each; data not shown).
(B) PrP protein in spleens and granulomas of
Prnp+/+, Prnp/, and tga20 mice as detected
by sandwich ELISA. Overall PrP levels increased
over time (Prnp+/+ spleens: p = 0.01; Prnp+/+ gran-
ulomas: p = 0.04).
respective spleens (Figure 2B and
Figure S2B). Granulomas and spleens of
tga20 mice displayed 2- to 5-fold greater
PrP concentrations than those of Prnp+/+
mice. At 95 dpi, a rise in total PrP was ob-
served in both granulomas and spleens,
possibly reflecting deposition of PrPSc.
No PrPC protein was detected in normal
Prnp+/+ subcutaneous tissues and in
spleens and granulomas of Prnp/ mice
(Figure 2B).
We then investigated Prnp promoter
activity in granulomas of PrnpGFP/GFP
mice whose PrP coding sequence was
replaced by the green fluorescent protein (GFP) through gene
targeting (Figure S3A). At 50 dpgi, GFP+ cells were detected in
centers, fibroblast cuffs, and fibrous capsules of PrnpGFP/GFP
granulomas (Figure S3A). Two-channel fluorescence micros-
copy revealed Prnp promoter activity in many, but not all,
LTbR+ mostly stromal cells and some I-A+, I-E+, and CD68+
macrophages (Figure S3B). Therefore, some stromal and hema-
topoietic cells within granulomas display Prnp promoter activity.
Alternatively CD68+ macrophages may have phagocytosed
GFP+ material.
PrPSc Is Produced Autochthonously within Granulomas
The presence of PrPSc at 55 and 95 dpi was assessed by sodium
phosphotungstate (NaPTA) precipitation followed by immuno-
blot analysis of granuloma (Figure 3A, left panel) and spleen ho-
mogenates (Figure 3A, right panel). All Prnp+/+ spleens displayed
PrPSc at both 55 and 95 dpi (Figure 3A). Prnp+/+ granulomas dis-
played PrPSc in one of three mice at 55 dpi, and in three of three
mice at 95 dpi (Figure 3A and Figure S4A), whereas all Prnp/
granulomas and spleens (n = 12) lacked PrPSc (Figure 3A and
Figure S4A). We additionally tested whether spleens, granulomas,
and skin (including superficial subcutaneous tissue) surrounding
granulomas contained prion infectivity. Tissue homogenates de-
rived fromPrnp+/+ andPrnp/ mice (55 and 95 dpi) were injected
intracerebrally (i.c.) into tga20 indicator mice and monitored clin-
ically (Figures 3B and 3C).Prnp+/+ spleen homogenates displayed
sizeable prion infectivity (4.3–5.5 logLD /g tissue) at 55 and50
1000 Immunity 29, 998–1008, December 19, 2008 ª2008 Elsevier Inc.
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Lymphotoxin and Prion Replication in Granulomas95 dpi, whereasPrnp+/+ granulomas had 1.8–2.6 logLD50/g in two
of three mice at 55 dpi and 1.9-3 logLD50/g in three of three mice
at 95 dpi (Figures 3B and 3C). Prnp/ granuloma or skin homog-
enates derived from Prnp+/+ and Prnp/ mice lacked prion infec-
tivity at 55 and 95 dpi. Each case of clinically diagnosed terminal
prion disease was confirmed by histology and immunohisto-
chemistry (Figure S4B).
To visualize PrPSc within granulomas, we performed histoblot
analyses of granulomas from prion-inoculated Prnp+/+ and
Prnp/ mice on consecutive cryosections (Figure 3D). PrPSc
was found mainly within granuloma centers and fibroblast cuffs
of Prnp+/+ mice at 55 (data not shown) and 95 dpi (Figure 3E).
Granulomas of prion-inoculated Prnp/ mice were devoid of
PrPSc (Figure 3E). Brain sections of RML-inoculated Prnp+/+
and Prnp/ mice were used for control (Figure 3E, insert). We
Figure 3. Prion Infectivity and PrPSc in
Granulomas
(A) PrPSc detection by NaPTA-enhanced immuno-
blotting of granuloma (left panel) and splenic (right
panel) homogenates from Prnp+/+ and Prnp/
mice (95 dpi). Scrapie-sick Prnp+/+ brain homoge-
nate (2.5 mg, first lane) and noninfected Prnp/
granulomas (250 ml of a 10% w/v homogenate)
spiked with scrapie-sick Prnp+/+ brain homoge-
nate (25 mg, lanes 2 and 9) were used as positive
controls. ‘‘S’’ refers to spike. All homogenates
except lane 1 were digested with proteinase K.
(B and C) Prion-infectivity titers of Prnp+/+ and
Prnp/ spleen, granuloma, and skin homoge-
nates isolated at (B) 55 and (C) 95 dpi. Infectivity
titers were assessed by mouse bioassay. Vertical
dotted lines separate individual Prnp+/+ and
Prnp/ mice. Each symbol represents the aver-
age of three to four intracerebrally inoculated
tga20 mice. Values above the dashed horizontal
line represent attack rates of 100%, whereas
values below the line indicate that <100% of indi-
cator animals developed scrapie.
(D and E) H&E staining (D) and corresponding
histoblot analysis (E) of consecutive cryosections
derived from granulomas of Prnp/ and Prnp+/+
mice at 95 dpi. PrPSc is located mainly within the
fibroblast cuffs of granuloma nodules (indicated
by arrows and dotted lines). Scale bars represent
150 mm. The inset in (E) shows a RML-inoculated
scrapie-sick Prnp+/+ brain, used as positive
control. The scale bar represents 500 mm. No
signal was detected in brains of RML-inoculated
Prnp/ mice.
conclude that both prion infectivity and
PrPSc accumulate in granulomas.
Establishment of Chimeric
Granulomas
We then sought to define the cellular
compartment supporting PrPC protein
expression and prion replication. We
performed reciprocal bone marrow (BM)
reconstitution experiments (Prnp+/+/
Prnp+/+; Prnp+/+/Prnp/; Prnp//
Prnp+/+; and Prnp//Prnp/) and assessed reconstitution
efficiency by flow-cytometry analysis for cell-surface PrPC
using Cy5-labeled POM2 antibody (Polymenidou et al., 2005).
Reconstitution of Prnp/ mice with Prnp+/+ BM restored
cell-surface PrPC expression on peripheral lymphocytes
similarly to Prnp+/+ mice (Figure 4A and Figure S5A). Conversely,
Prnp+/+ mice reconstituted with Prnp/ BM showed
almost complete absence of PrPC-expressing cells from
peripheral blood (Figure 4A). Next, we induced granulomas in
Prnp+/+/Prnp/ and Prnp//Prnp+/+ chimeras, as well as
in Prnp/ and Prnp+/+ mice. Granulomas and spleens of Prnp+/+
and Prnp//Prnp+/+ mice displayed PrPC concentrations
of ca. 5–15 ng/mg tissue, whereas granulomas and spleens of
Prnp/ and Prnp+/+/Prnp/ mice contained very little or
<2 ng/mg PrPC (Figure 4B, left panel). Therefore, PrPC wasImmunity 29, 998–1008, December 19, 2008 ª2008 Elsevier Inc. 1001
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Lymphotoxin and Prion Replication in Granulomaspredominantly produced by radioresistant cells in both granulo-
mas and spleens.
Theoretically, PrPC expression in granulomas of BM-chimeric
mice (Prnp//Prnp+/+) may be contributed by residual radiore-
sistant hematopoietic cells. We addressed this by generating
reciprocal b-Actin-GFP and C57BL/6 BM-chimeras (b-actin-
GFP/C57BL/6 and C57BL/6/b-actin-GFP; Figures S5B and
S5C). Reconstitution efficiency, as assessed by identification
of donor-derived blood cells in C57BL/6 mice receiving
b-actin-GFP BM, was 88%–94%. We then counted CD68+GFP+
and B220+GFP+ cells at 13 weeks after reconstitution (ca.
50 dpgi) in several serial sections of granulomas. In granulomas
from three individual C57BL/6/b-Actin-GFP chimeric mice ca.
6% ± 3% of CD68+ and 9% ± 4% of B220+ cells were GFP+. In
contrast, in granulomas of b-actin-GFP/C57BL/6 chimeric
mice (n = 3), the majority of CD68+ (84% ± 4%) and B220+
(83% ± 7%) cells were GFP+ (Figures S5B and S5C). Therefore,
very few if any residual B220+ or CD68+ radioresistant hemato-
poietic cells are present in granulomas and are unlikely to
account for the relatively high PrPC expression in granulomas
of chimeric Prnp//Prnp+/+ mice.
The Stromal Compartment of Granulomas
Replicates Prions
We then investigated the contribution of the radioresistant com-
partment to prion pathogenesis within granulomas. Chimeric
mice (Prnp+/+/Prnp/; Prnp+/+/Prnp+/+; Prnp//Prnp/;
andPrnp//Prnp+/+) were inoculated i.p. with 5 logLD50 prions
(RML6) at 50 dpgi, and analyzed at 95 dpi (Figures S6A and S6B).
PrPSc in granulomas was assessed by NaPTA precipitation and
then by immunoblot analysis. At 95 dpi, all Prnp//Prnp+/+
and Prnp+/+/Prnp+/+ granulomas, but no Prnp+/+/Prnp/
and Prnp//Prnp/ granulomas, displayed PrPSc (n = 6 in
each group; Figures S6 and S7A).
To evaluate prion-infectivity titers, we performed scrapie cell
assays (Klohn et al., 2003) in endpoint format (SCEPA) with
spleen and granuloma homogenates from the same individual
chimeric mice that had been subjected to immunoblot analysis.
Brain homogenates derived from terminally scrapie-sick or
healthy mice were used for calibrating and ascertaining the
detection limit of the SCEPA (Supplemental Data). Sustained
prion infectivity was detected in all Prnp+/+/Prnp/ (n = 4),
Prnp+/+/Prnp+/+ (n = 2), and Prnp//Prnp+/+ spleens (n = 4),
but not in Prnp//Prnp/ spleens (n = 2) (Figure 5A, Figures
S6 and S8, and Table 1), in agreement with previous reports
(Bla¨ttler et al., 1997; Kaeser et al., 2001; Priller et al., 2006).
Chimeric Prnp+/+/Prnp+/+ and Prnp//Prnp+/+ granulo-
mas (n = 7) displayed titers of R6.1 log TCI units/g (Figure 5B,
Figure S8, and Table 1), whereas no infectivity was detectable
in Prnp+/+/Prnp/ and Prnp//Prnp/ granulomas (n = 6).
Therefore, prion-infectivity titers in granulomas of Prnp/ BM
recipients were consistently R3.3 logs lower than those of
Prnp+/+ recipients (Table 1).
Administration of soluble dimeric LTbR leads to the rapid dis-
appearance of FDCs from spleen (Mackay and Browning, 1998)
and was previously found to interfere with splenic prion replica-
tion (Aguzzi and Heikenwalder, 2006; Mabbott et al., 2000;
Montrasio et al., 2000). Because granulomas expressed LTbR
(Figure 2), prion replication within granulomas may also depend
on LT signaling. We examined this question by treating granu-
loma-bearing, prion-infected mice with LTbR-Fc. Fifty dpgi, we
inoculated mice i.p. with prions (RML5; 5 logLD50). At 55 dpi,
we injected either LTbR-Fc or pooled human immunoglobulins
(Hu-IgG) as control (100 mg/injection) (Montrasio et al., 2000)
weekly for up to 6 weeks. Neither LTbR-Fc nor Hu-IgG treatment
was found to exert any effect on the size of granulomas (data not
shown). Immunohistochemistry and histoblot analyses con-
firmed the dedifferentiation of FDCs and suppression of splenic
PrPSc accumulation in LTbR-Fc treated, but not in Hu-IgG
treated, mice (Figures S7B and S7C).
Granulomas were then isolated and homogenized, and prion-
infectivity titers were determined by SCEPA (Klohn et al., 2003)
(Figure 5C, Figure S8, and Table 1). All Hu-IgG treated granulo-
mas displayed prion-infectivity titers of R4 log TCI units/g. In
Figure 4. The Stromal Compartment of Granulomas Facilitates
Efficient PrPC Expression
(A) Flow-cytometry analysis of surface PrPC expression in live-gated peripheral
blood lymphocytes. Left two columns show unstained and POM2-Cy5 stained
lymphocytes from peripheral blood of Prnp/, Prnp+/+, and tga20 mice. Num-
bers in the quadrants represent the relative percentages of cells. Each panel
represents one individual mouse.
(B) PrPC content of granulomas and spleens as determined by ELISA at
50 dpgi. Each bar represents one individual mouse. Error bars indicate the
standard deviation (SD) of three technical replicates.1002 Immunity 29, 998–1008, December 19, 2008 ª2008 Elsevier Inc.
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treated with LTbR-Fc fusion protein (detection threshold: 2.8 log
TCI units/g). The two remaining granulomas displayed 3.5 and
R4.8 log TCI units/g (Figure 5C and Table 1). Therefore, LTbR-
Fc treatment markedly reduced the prion load of granulomas
(p < 0.02).
Identity of Prion-Replicating Cells in Granulomas
We first compared the number and size distribution of dissoci-
ated cells from untreated, LTbR-Fc, or Hu-IgG treated granulo-
mas as well as from naive spleens by flow cytometry
(Figure 6A and Figures S9 and S10). The morphological identity
of recovered cells was confirmed by Papanicolaou-stained cyto-
spin preparations. Whereas splenic cell suspensions contained
lymphocytes (6–7 mm) and larger cells (macrophages and
granulocytes, 8–9 mm), granulomas were almost exclusively
composed of larger cells (macrophages, granulocytes, and
fibroblasts, etc.; Figure 6A and Figure S9). The viability of granu-
lomas treated with LTbR-Fc or Hu-IgG was 65% ± 18% and
66% ± 7%, respectively (p = 0.9).
Flow-cytometry analysis revealed a mostly CD45, GFP+ cell
population within granulomas of PrnpGFP/GFP mice (Figure 6A).
Figure 5. Prions Accumulate in a Radiore-
sistant, LTbR-Signaling-Dependent Com-
partment of Granulomas
Prion-infectivity titers of spleens and granulomas
were determined by scrapie cell assay in endpoint
format (SCEPA). Transfer of prion infectivity to
cells results in PrPSc+ colonies, which in turn con-
fer a spotted dark stain to ELISPOT membranes.
Membranes with >3 PrPSc+ colonies (asterisks)
were regarded as infected.
(A) Prion infectivity in splenic homogenates of chi-
meric Prnp+/+/Prnp/, Prnp//Prnp+/+ (left
panel), and Prnp+/+/Prnp+/+ mice but not in
spleens of Prnp//Prnp/ mice (right panel;
see also Table 1). Positive (RML6; 300,000 LD50
units in 200 mg) and negative (Mock: healthy
mouse brain homogenate; 200 mg) controls are in-
dicated. Each row represents an individual mouse.
The range of granuloma-derived protein added
per well is indicated.
(B) Prion infectivity in chimeric granulomas with
a Prnp+/+ stromal compartment (Prnp+/+/Prnp+/+
and Prnp//Prnp+/+ mice). ‘‘Ctrl.’’ refers to con-
trols. Each row represents an individual mouse.
(C) Effect of LTbR-Fc or Hu-IgG treatment on prion
infectivity of granulomas. Whereas Hu-IgG treat-
ment had no effect on prion content of granulomas
(n = 6), LTbR-Fc treatment suppressed prion titers
in five of seven granulomas. Each row represents
an individual mouse. Horizontal lines demarcate
two independent experiments. ‘‘Ctrl.’’ refers to
controls.
Table 1. Quantitative Prion-Infectivity Determinations in Granulomas, Spleens, and Brains
Mouse Organ Treatment dpi Log TCI Units/g of Tissue
CD1 brain (RML6 standard) - pooled 8.3, 8.3 (two independent
determinations)
Prnp//Prnp+/+ spleen - 95 R6.1 in 4/4 mice
Prnp+/+/Prnp/ spleen - 95 R6.1 in 4/4 mice
Prnp+/+/Prnp+/+ spleen - 95 R6.1 in 2/2 mice
Prnp//Prnp/ spleen - 95 % 2.8 in 2/2 mice
Prnp//Prnp+/+ granuloma - 95 R6.1 in 3/3 mice
Prnp+/+/Prnp/ granuloma - 95 %2.8 in 3/3 mice
Prnp+/+/Prnp+/+ granuloma - 95 R6.1 in 3/3 mice
Prnp//Prnp/ granuloma - 95 %2.8 in 3/3 mice
Prnp+/+ granuloma LTbR-Fc 95 R4.8 in 1/7 mice, =3.5 in 1/7
mice,%2.8 in 5/7 mice
Prnp+/+ granuloma Hu-IgG 95 R4.8 in 4/6 mice, =4 in 2/6 mice
Titers were calculated as described (Klohn et al., 2003). Infectivity was assessed by SCEPA.Immunity 29, 998–1008, December 19, 2008 ª2008 Elsevier Inc. 1003
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podoplanin (gp38), CD45GFP+ cells were gp38 and did not
appear to express vascular cell adhesion molecule-1 (VCAM-1)
or platelet and endothelial cell adhesion molecule-1 (CD31 or
PECAM) (Figure S10). Further characterization of the
CD45GFP+ population revealed that those cells express LTbR
and CD34 and are positive for platelet-derived growth factor
receptors a and b (PDGFRa and b), suggesting a mesenchymal
origin (Figure 6A and Figure S10). This was also reproduced in
granulomas of wild-type mice, in which we could identify the
same CD45PrP+LTbR+ population (Figure S10).
Six weeks of LTbR-Fc or Hu-IgG treatment did not significantly
affect the main cell populations within granulomas. Flow-cytom-
etry analysis identified a slight reduction of CD11b+CD45+ mac-
rophages in LTbR-Fc treated granulomas (LTbR-Fc: 56 ± 5;
Hu-IgG: 72 ± 10; p = 0.06; Figure 6B), and the number of
CD45-PrP+LTbR+ cells was unchanged (LTbR-Fc: 5.6% ± 3%;
Hu-IgG: 5.1% ± 3%; p = 0.88) (Figure 6C). Immunostains
(CD11b, CD11c, MHCII, FDC-M1, CD3, and B220) failed to re-
veal differences between LTbR-Fc- and Hu-IgG-treated granulo-
mas (Figure S11). Prnp and Ltbr transcription and PrPC protein
concentration were similar in LTbR-Fc- and Hu-IgG-treated
granulomas (Figure S12). However, LTbR-Fc-treated granulo-
mas displayed significantly reduced mRNA expression of the
LTbR targets Ccl2 (25%–5% ; p < 0.05) and Icam1(50%–5%,
p < 0.05), but not of Ccl5 and Vcam1.
DISCUSSION
Chronic inflammatory conditions are ubiquitous in the entire an-
imal kingdom, ranging from autoimmunity to bacterial, fungal,
and viral infections and persistent foreign bodies. Each of these
pathogenetic groups is associated with distinct morphological
and cellular features. Autoimmune diseases and chronic bacte-
rial infections can induce lymphoid follicles with prominent
FDC networks (Drayton et al., 2006), which can replicate prions
in mice (Heikenwalder et al., 2005; Seeger et al., 2005), sheep (Li-
gios et al., 2005), and deer (Hamir et al., 2006). However, chronic
inflammation more commonly gives rise to granulomas (Kumar
et al., 2004) whose cellular composition is different from that of
lymphoid follicles. Granulomas occur, for example, in Crohn’s
disease, sarcoidosis (Iannuzzi et al., 2007), and most mycobac-
terial (Britton and Lockwood, 2004; Ernst et al., 2007; Russell,
2007), fungal, and parasitic infections, as well as in foreign-
body reactions. Because of their importance for human and vet-
erinary medicine, we sought to determine whether granulomas
may have prion-replication competence.
We found that granulomas displayed surprisingly high PrPC
concentrations approaching the relatively high levels seen in
Figure 6. LTbR-Fc Treatment Does Not Change PrPc Expression on
Stromal Cells of Granulomas
(A) Flow-cytometry analysis of granulomas derived from PrnpGFP/GFP and
wild-type mice treated with Hu-IgG or LTbR-Fc. The upper-left panel shows
forward (FSC) and sideward scatter (SSC) and live gate (black gate) of a gran-
uloma cell suspension. The upper-right panel shows a dot plot depicting the
GFP+CD45- population detected in unstained granuloma cell suspensions of
PrnpGFP/GFP mice (9.97% of all granuloma cells). Fluorescent intensities are
depicted in a log scale.
(B) Histograms characterizing the gated GFP+ cell population of PrnpGFP/GFP
granuloma for the expression of various markers. GFP+CD45- cells were
LTbR+, CD34+, and PDGFRab+ (black graphs). Hollow, gray graphs depict
the appropriate isotype controls used.
(C) Flow-cytometry analysis of Hu-IgG or LTbR-Fc treated, live-gated wild-
type granuloma cell suspensions for CD11b+CD45+, CD45-PrP+ (left panel)
or CD45-LTbR+ (right panel) granuloma cell populations.
(D) Flow-cytometry analysis of Hu-IgG or LTbR-Fc treated, live-gated,
CD45- wild-type granuloma cell suspensions for PrPC or LTbR surface expres-
sion. LTbR-Fc- (black graph) or Hu-IgG- (hollow, gray graph) treated mice are
indicated. Mean fluorescence intensities (MFIs) for PrPC surface expression
are as follows: LTbR-Fc: 140 ± 12; Hu-IgG: 133 ± 12; p = 0.5; MFI for LTbR
surface expression: LTbR-Fc: 204 ± 34; Hu-IgG: 209 ± 5; p = 0.8). At least three
independent experiments were performed.1004 Immunity 29, 998–1008, December 19, 2008 ª2008 Elsevier Inc.
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detectable PrPC mRNA or protein, some granuloma-specific
cells must thus express very high amounts of PrPC. This finding
applied to both CFA and Z/PFO-induced granulomas despite
their markedly different cellular composition.
Reciprocal bone-marrow grafting experiments indicated that
radioresistant cells accounted for most of the PrPC found in
granulomas, whereas radiosensitive cells did not appreciably
contribute to the PrPC content of granulomas. Hence, granulo-
matous inflammation induces PrPC expression in preexisting
stromal cells or maybe leads to the mobilization and recruitment
of PrPC-expressing stromal cells originally residing at other sites.
Granulomas of prion-inoculated Prnp+/+ mice were found to
consistently display PrPSc and prion infectivity. This was surpris-
ing because granulomas lacked FDCs, which are essential to
lymphoid and extraneural prion replication in several paradigms
(Hamir et al., 2006; Heikenwalder et al., 2005; Ligios et al., 2005;
Mabbott et al., 2000; Montrasio et al., 2000).
Granulomas lacked Mfge8 mRNA, an early marker of FDC dif-
ferentiation (Kranich et al., 2008). We therefore investigated
whether the above results may stem from inoculum retention
rather than local prion replication. This, however, is unlikely
because (1) granulomas of Prnp/ mice were always devoid
of infectivity and (2) the proportion of prion-positive granulomas
at 95 dpi was greater than at 55 dpi, whereas simple prion
retention would intuitively be expected to decrease over time.
Alternatively, infectivity of granulomas may plausibly represent
‘‘spill-over’’ from other extraneural sites of prion replication,
such as the lymphoid organs. However, granulomas of
Prnp+/+/Prnp/ chimeric mice completely lacked any prion in-
fectivity, although their spleens displayed prion-infectivity titers
similar to those of wild-type mice (Bla¨ttler et al., 1997; Kaeser
et al., 2001; Priller et al., 2006). This finding suggests that prion
uptake from other sites of replication is highly unlikely. Notably,
homogenates of skin located in the immediate vicinity of granu-
lomas lacked prion infectivity in both Prnp+/+ and Prnp/ mice
at 55 and 95 dpi. This is in agreement with the report that the
skin may carry prions only at late stages of disease (Thomzig
et al., 2007).
Our findings unambiguously indicate that prions replicate in
the nonhematopoietic compartment of granulomas. The latter
contains predominantly fibroblasts, which were found to repli-
cate prions in vitro (Vorberg et al., 2004), and—to a much lesser
extent—endothelia, pericytes, and possibly some nerve endings
and contaminating skin constituents. Some of these cell types
(notably including fibroblasts) cannot be unequivocally identified
with unique markers, and current technology does not allow for
identifying prion replication at the single-cell level. Therefore,
we opted to define the nature of the cells enabling granuloma-
tous prion replication by virtue of their dependence on specific
signaling pathways.
Prion invasion of spleen, lymph nodes, and Peyer’s patches is
completely dependent on lymphotoxin signaling (Mabbott et al.,
2000; Montrasio et al., 2000). Because the latter is required for
the differentiation and maintenance of FDCs (Mackay and
Browning, 1998; Mackay et al., 1997), it was initially speculated
that FDCs may be obligatorily required for extraneural prion rep-
lication. However, a growing body of evidence suggests a more
nuanced situation. Although crucially dependent on lymphotoxinImmsignaling in all conditions investigated, extraneuronal prion
replication was found to occur in the absence of immunohisto-
chemically recognizable FDCs in various paradigms (Dlakic
et al., 2007; Kovacs et al., 2004; Oldstone et al., 2002; Prinz
et al., 2002; Vorberg et al., 1999). Accordingly, Tnfr1/ mice
accumulate prions in lymph nodes despite the absence of
FDCs, whereas mice deficient in LTs or their receptor are largely
resistant (Klein et al., 1997; Prinz et al., 2002).
Although they did not contain any FDCs, granulomas ex-
pressed almost equal amounts of LtbrmRNA asPrnp+/+ spleens.
LTbR-Fc treatment did not alter PrPC expression but suppressed
prion replication within granulomas by at least two orders of
magnitude without affecting their formation, maintenance, and
overall morphology. These results indicate that stromal cells
other than FDCs can acquire prion-replication competence
in vivo in a LTbR-signaling-dependent manner. What is the na-
ture of these cells? A plausible candidate is the fibroblastic retic-
ular cell (FRC) that was identified within lymphoid organs (Link
et al., 2007) and possibly at inflammatory lesions (G. Eberl
et al., personal communication). FRC maintenance and function
depend on LTbR signaling (Scandella et al., 2008). All these char-
acteristics are congruent with the defining traits of prion-replicat-
ing cells within granulomas. FRC maturation relies on interac-
tions with LT-expressing lymphoid tissue inducer cells (LTis),
suggesting that LTis may play a major role in prion pathogenesis.
We characterized the PrPC-expressing stromal cell within
granulomas in more detail by flow-cytometry analysis and addi-
tionally investigated the effects of LTbR-Fc treatment on granu-
lomas. The prion-replicating cells within granulomas display
overlapping features with FRCs of secondary lymphoid organs,
given that FRCs also express LTbR (Link et al., 2007) and
PrPC (S. Luther, personal communication). However, prion-rep-
licating cells within granulomas are most likely mesenchymal
because they express PDGFRa and b and are not classical
CD45gp38+VCAM-1+ FRCs (Link et al., 2007) because granulo-
mas lacked Ccl19 and Ccl21. It is possible that those cells stem
from FRC progenitors undergoing atypical differentiation.
LTbR-Fc treatment did not deplete CD45gp38CD31
VCAM-1CD34+PDGFRab+ PrP+LTbR+ cells nor did it markedly
reduce the expression of PrPC or LTbR, yet it reduced expres-
sion of a number of LTbR target genes. Therefore, LT signaling
is likely to play an important role in licensing prion replication to
granulomas independently of the formation of lymphoid folli-
cles, the maturation of FDCs, and the expression of Mfge8.
Because granulomas can occur at any site of the body, these
results suggest that prions may colonize a broader spectrum
of organs than previously anticipated. With respect to the rele-
vance of the above findings for hospital hygiene (e.g., iatrogenic
prion transmission in humans) and for veterinary medicine (e.g.,
prion shedding in animals), it will be interesting to test whether
prion replication in granulomas occurs in farm animals and in
humans.
EXPERIMENTAL PROCEDURES
Mice and Scrapie Inoculation
C57BL/6, congenic C57BL/6 b-actin-GFP mice (Jackson Laboratories)
(Okabe et al., 1997), C57BL/6 3 129Sv (Prnp+/+), Prnp/ (Bu¨eler et al.,
1992), Ltbr/, Lta/, Mfge8/ (De Togni et al., 1994; Futterer et al., 1998;unity 29, 998–1008, December 19, 2008 ª2008 Elsevier Inc. 1005
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under specific pathogen-free (SPF) conditions. Housing and experimental
protocols were in accordance with the Swiss Animal Protection Law and in
compliance with the regulations of the Veterina¨ramt, Kanton Zu¨rich. Mice
were infected intraperitoneally (i.p.) with 100 ml brain homogenate derived
from terminally scrapie sick CD-1 mice. Brain material was homogenized in
PBS/0.32M sucrose, containing 5 logLD50 of the Rocky Mountain laboratory
(RML) scrapie strain (passage 5) (Kaeser et al., 2001) or RML6 (Falsig et al.,
2008). Mice were euthanized at 0, 55, and 95 dpi in accordance with the stan-
dard operating procedures and the Swiss Animal Protection Law.
Generation of Chimeric Mice
A total of 1 to 2 3 107 BM cells were isolated from tibiae and femurs and
injected into tail veins of 8- to 12-week-old recipients conditioned by whole-
body irradiation (1100 rad). Six to eight weeks after grafting, reconstitution
was assessed by FACS analysis of peripheral blood taken from the tail vein.
Induction of Granulomas
Granulomas were induced subcutaneously (s.c.) at two symmetric abdominal
sites (left and right) in C57BL/6, b-actin-GFP, C57BL/6 3 129Sv (wild-type),
PrnpGFP/GFP, tga20, and Prnp/ mice by CFA or Z/PFO emulsified in the
identical amount of sterile PBS. At 25 dpgi, a second injection was performed
in the immediate vicinity of the injection site. For analysis, granulomas were
dissected, pooled, and subjected to immunohistochemical and WB analysis,
ELISA, RNA purification, transmission assay and SCEPA.
LTbR-Fc and Hu-IgG Treatment
Prnp+/+ mice were i.p. injected weekly with 100 mg LTbR-Fc or Hu-IgG (kindly
provided by J. Browning; Biogen). Treatment was performed for 6 weeks.
Statistical Analysis
The effect of LTbR-Fc and Hu-IgG treatment on prion replication in granulomas
of mice was analyzed with ordinal variables with three categories (<2.8,
2.8–4.8, and > 4.8 log TCI units). SPSS 15.0 (SPSS, Inc.) was used for statis-
tical analyses. Groups were compared with the Mann-Whitney test with exact
p values. For other statistical analyses, Student’s t tests were performed.
Histology, Histoblot, and Immunohistochemistry
Paraffin sections (2 mm) and frozen sections (5 or 10 mm) of spleen, granuloma,
and brain were stained with hematoxylin and eosin or various primary and
secondary antibodies (Supplemental Data). Histoblot analysis was performed
as described (Taraboulos et al., 1992).
RNA Isolation from Granulomas and Real-Time PCR Analysis
Flash-frozen granulomas were dissolved in RNA isolation buffer (RLT;
QIAGEN) and homogenized with a homogenizer (Dispomix, Medic Tools).
RNA was purified as described by the manufacturer’s manual (QIAGEN).
cDNA generation was performed with a QuantiTect, Reverse Transcription
kit (Cat. No. 205313), and real-time PCR analysis was performed as
recently described with a QuantiFast SYBR Green PCR kit (Cat. No.204052)
(Heikenwalder et al., 2005). Primer combinations used are indicated in the
Supplemental Data.
PrP Sandwich ELISA
Ninety-six-well plates were coated with 400 ng/ml of purified POM1 antibody
overnight at 4C. Plates were washed with PBS containing 0.1% (vol/vol)
Tween 20 (PBST) and blocked with 5% Top Block for 2 hr at room temperature
(RT). After washing, plates were incubated with 100 ml of granuloma homoge-
nates containing 1 mg/ml total protein. Protein content of granuloma homog-
enates was assessed by a standard colorimetric method based on bicincho-
ninic acid (BCA, Pierce). Samples were analyzed in quadruplicates. For the
standard curve, 2-fold serial dilutions of recombinant mouse PrP23-230 in
PBST/1% Top Block were applied (volume 100 ml), starting from a 50 ng/ml
concentration. After 1 hr at RT, plates were washed extensively and then
probed with biotinylated POM2 (Polymenidou et al., 2005) at a concentration
of 200 ng/ml in PBST containing 1% Top Block for 1 hr at room temperature.
After washing, plates were incubated with horseradish peroxidase-conjugated
Avidin (1:5000 dilution, Invitrogen) for 1 hr at RT. Plates were developed with1006 Immunity 29, 998–1008, December 19, 2008 ª2008 Elsevier In2.2-azino-diethyl-benzothiazolinsulfonate (Boehringer), and optical density
was measured at 405 nm. With the limiting dilution of recombinant mouse
PrP23-230 solutions of known concentrations, a standard curve was generated.
On the basis of the standard curve, we calculated PrPC concentration in each
well containing sample. Standard deviation was calculated from technical
quadruplicates of the samples. Limit of detection is 2 ng/ml, representing
23 background level. In rare cases, we observed that Prnp/ granuloma
samples displayed increased background levels (up to 4 ng/ml). In those
cases, averaged background values were subtracted from Prnp+/+ values.
Flow-Cytometric Analysis
Prior to FACS analysis, each granuloma was isolated, and caseous liquid
was removed and enzymatically digested in 4 ml RPMI containing 10% FCS,
3 mg/ml Collagenase D (Roche), and 0.8mg/ml DNase (Sigma) for 1 hr at
37C. Released cells were filtered through a 70 mm nylon mesh, collected by
centrifugation, resuspended in PBS containing 2% FCS, and filtered again
through a 40 mm nylon mesh. The cells were then incubated with various
primary and secondary antibodies (Supplemental Data).
Generation of PrnpGFP/GFP Mice
The two step ‘‘tag-and-exchange’’ method of gene-targeting was used to
replace the entire protein coding sequence of the PrP gene (Prnp) with DNA
sequence encoding the enhanced green fluorescent protein (EGFP) in mouse
embryonic stem cells (ESCs) (Moore et al., 1995; Selfridge et al., 1992)
(Figure S3A). For the first step, a ‘‘tag construct’’ undergoes homologous re-
combination with one endogenous Prnp allele, resulting in deletion of a section
of Prnp and insertion of a hypoxanthine phosporibosyltransferase (Hprt) mini-
gene, resulting in a knockout allele. The presence of the Hprt minigene confers
resistance to HAT media, which will kill ESCs not integrating theHprtminigene.
For the second step, knockout ESCs were modified with an exchange con-
struct replacing theHprtminigene with the EGFP sequence by homologous re-
combination. The Prnp-GFP allele differs from the wild-type Prnp allele by the
inclusion of a BamHI restriction endonuclease site adjacent to the EGFP
coding sequence, detected by genomic Southern analysis with a probe
homologous to a region of Prnp downstream of the targeting constructs. Cor-
rectly targeted ESCs were injected into 3.5 day P.C. embryos from C57BL/6
Taconic mice. Injected embryos were then implanted into pseudopregnant
females (CD1). We then bred chimeric mice to C57Bl/6 mice to establish the
PrnpGFP/GFP mouse line.
Scrapie Cell Assay in End Point Format
This assay was performed as previously described by (Klohn et al., 2003). Rep-
licate aliquots of highly prion-susceptible neuroblastoma cells (subclone
N2aPK1) were placed into 4–24 wells of a 96-well plate and exposed to
inoculum control (RML6) or prion samples (granuloma and splenic tissue
homogenized and diluted from 103 to 106) for 3 days, split 1:3 three times
every 2 days, and split 1:10 four times every 3 days. After reaching confluence,
2 3 104 cells from each well were filtered onto the membrane of an ELISPOT
plate (Millipore; MultiScreenHTS filter plates with Immobilon-P PVDF mem-
brane), treated with PK and denatured, and individual infected (PrPSc-positive)
cells were detected immunochemically with PrP antibody POM1 to PrP (Poly-
menidou et al., 2005). Wells were scored positive if the spot number exceeded
mean background values added by three times the standard deviation of the
MOCK control. Here, an ELISPOT membrane withR3 PrPSc+ colonies (aster-
isks) was regarded as infected (see Figure 5). From the proportion of negative
to total wells, the number of tissue culture infectious units per ml was calcu-
lated with the Poisson equation.
In two independent experiments, a 108 dilution of a standard inoculum
(brain homogenate from a terminally scrapie-sick mouse) yielded 11/24 or
12/24 positive wells, corresponding to a titer of8.3 log tissue culture infectiv-
ity (TCI) units/g of brain tissue for the initial inoculum (Figures S6 and S8 and
Table 1). The sensitivity threshold was calculated to be 2.8 log TCI units/g of
brain tissue.
Infectivity Bioassay with tga20 Indicator Mice
Assays were performed on 10% splenic, granuloma, and cutaneous homoge-
nates. For granuloma homogenization, granulomas were isolated from the
subcutis and skin and fatty tissue were removed. Granulomas were choppedc.
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approximately 1–2 cm2 were used for homogenization. All tissues were diluted
in PBS, homogenized with a homogenizer (Precellys 24; Bertin Technologies)
in four rounds of homogenization (depending on the tissue) for 30 s, and sub-
sequently cooled on ice for 5 min between each cycle. When homogenous, so-
lution was spun for 1 min at 500 g. Supernatants (30 ml) of granuloma, cutane-
ous, and splenic homogenates were inoculated intracerebrally into groups of
three to four tga20 mice (Fischer et al., 1996). Tga20 mice were monitored until
the terminal stage of disease and euthanized according to the standard oper-
ating procedures. The relationship y = 11.45  0.088x (y, log LD50 per milliliter
of homogenate; x, incubation time in days to terminal disease) was calculated
by linear regression (Kaeser et al., 2001; Prusiner et al., 1982).
Immunoblot Analysis and Sodium Phosphotungstate Precipitation
Tissue homogenates (brain and spleen) were adjusted to 8 mg/ml protein and
treated with proteinase K (20–50 mg/ml, 30 min, 37C). We electrophoresed
50 mg total protein through a SDS-PAGE gel (12%). Proteins were transferred
to nitrocellulose by wet-blotting. Membranes were blocked (TBST containing
5% nonfat milk), decorated with monoclonal antibody POM1 (Polymenidou
et al., 2005), and visualized by enhanced chemiluminescence (ECL, Socochim,
Pierce). For granuloma homogenates NaPTA precipitation was performed.
10% granuloma homogenates were prepared in PBS on ice. Gross cellular de-
bris was removed by centrifugation at 500 g for 1–2 min. The resulting super-
natant was adjusted to 500 ml with PBS and mixed 1:1 with 4% Sarkosyl in
PBS. Samples were incubated for 15 min at 37C under constant agitation.
Benzonase and MgCl2 were added to a final concentration of 50 U/ml and
1 mM, respectively, and incubated for 30 min at 37C under agitation. Pre-
warmed NaPTA stock solution (pH 7.4) was added to a final concentration of
0.3%, and the sample was incubated at 37C for 30 min with constant agitation
and then centrifuged at 37C for 30 min at 14000 g in an Eppendorf microcen-
trifuge. The pellet was resuspended in 30 ml 0.1% Sarkosyl in PBS and
digested with 30 mg/ml proteinase K (PK) for 60 min at 37C with agitation.
The sample was heated at 95C for 5 min in SDS-containing loading buffer
before loading onto 12% Novex SDS polyacrylamide gels (Invitrogen).
SUPPLEMENTAL DATA
Supplemental Data include Supplemental Experimental Procedures and
twelve figures and can be found with this article online at http://www.
immunity.com/supplemental/S1074-7613(08)00512-8.
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